When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MYOK - Dosing is underway in mid-stage study for MyoKardia's danicamtiv in heart disease
MyoKardia Inc.
MyoKardia (MYOK+0.9%) has dosed the first patient in Phase 2 trial of danicamtiv (MYK-491) in people with primary dilated cardiomyopathy (DCM), characterized by weakened and enlarged heart muscle, that results in the heart not being able to pump enough blood.
More news on: MyoKardia, Inc., Healthcare stocks news,